Comparative Pharmacology
Head-to-head clinical analysis: ADPHEN versus MELFIAT 105.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADPHEN versus MELFIAT 105.
ADPHEN vs MELFIAT-105
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adphen is a combination of phentermine hydrochloride and diethylpropion hydrochloride. Phentermine is a sympathomimetic amine that acts as an appetite suppressant by stimulating the hypothalamus to release norepinephrine, thereby reducing food intake. Diethylpropion also has sympathomimetic activity, though its exact mechanism is not fully understood.
Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity in the CNS by inhibiting reuptake of serotonin at the presynaptic neuronal membrane.
5 mg orally once daily, titrated to a maximum of 10 mg once daily as tolerated.
105 mg orally once daily in the morning.
None Documented
None Documented
Terminal elimination half-life is 10-15 hours in adults with normal renal function; prolonged to 20-30 hours in severe renal impairment (CrCl <30 mL/min).
The terminal elimination half-life is approximately 4-6 hours, supporting twice-daily dosing in clinical practice.
Primarily renal (70-90% as unchanged drug) with minor biliary (10-15% as metabolites). Fecal elimination is negligible (<5%).
Approximately 90% of an administered dose is excreted renally as unchanged drug and metabolites, with the remainder eliminated via biliary/fecal routes.
Category C
Category C
Anorexiant
Anorexiant